Alys Pharmaceuticals begins phase 1/1b trial of ALY-301 for chronic urticaria
30th October 2025 Uncategorised 0
First-in-class mast cell selective c-Kit inhibitor enters clinical testing in Germany

More: Alys Pharmaceuticals begins phase 1/1b trial of ALY-301 for chronic urticaria
Source: News
